Details

Autor(en) / Beteiligte

• Wannhoff, A
• Weiss, K.H
• Hackert, T
• Gotthardt, D.N

Titel

Comment re: “Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping”

Ist Teil von

• Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2017-05, Vol.17 (3), p.354-355

Ort / Verlag

Switzerland: Elsevier B.V

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Genotyping for FUT2 and FUT3 as well as CA19-9 measurement was performed in samples from 50 patients with chronic pancreatitis (control group) and 51 patients with pancreatic cancer. [...]Luo et al. found increased CA19-9 levels in cancer patients with a low CA19-9 biosynthesis genotype compared to cancer-free controls and reported an AUC of 0.82 for ROC analysis in this group. [...]the study by Lou et al. nicely proved the value of the FUT2 and FUT3 genotype in CA19-9 based screening for gastrointestinal cancer.Source of funding DNG was supported by a grant from Deutsche Forschungsgemeinschaft.Conflict of interest All authors declare that there is no conflict of interest. n CA19-9 P* P** Control Low 5 (10.0%) 5.0 (2.5–18.5) <0.001 Intermediate 36 (72.0%) 9.0 (7.0–12.0 High 9 (18.0%) 39.0 (20.5–198.5) Cancer Low 1 (2.0%) 4.0 0.064 0.667 Intermediate 40 (78.4%) 111.0 (20.3–382.3) <0.001 High 10 (19.6%) 351.0 (114.5–1015.5) 0.008 Table 1 CA19-9 levels according to CA19-9 biosynthesis genotype in control and cancer patients.